0001438133-20-000095.txt : 20200618 0001438133-20-000095.hdr.sgml : 20200618 20200617192612 ACCESSION NUMBER: 0001438133-20-000095 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200616 ITEM INFORMATION: Other Events FILED AS OF DATE: 20200618 DATE AS OF CHANGE: 20200617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 20970904 BUSINESS ADDRESS: STREET 1: 11075 ROSELLE STREET CITY: San Diego STATE: CA ZIP: 92121 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 11075 ROSELLE STREET CITY: San Diego STATE: CA ZIP: 92121 8-K 1 tndm-20200616.htm 8-K tndm-20200616
false000143813300014381332020-06-162020-06-16

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2020
 
____________________________
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
____________________________
 
Delaware001-3618920-4327508
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
11075 Roselle Street92121
San Diego California
(Zip Code)
(Address of principal executive offices)
 Registrant’s telephone number, including area code: (858) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassSymbolName of Exchange on Which Registered
Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________



Item 8.01 Other Events.
On June 16, 2020, the U.S. Food and Drug Administration (FDA) cleared an expanded pediatric indication for our t:slim X2™ insulin pump with Control-IQ™ technology to children age six and older. The product was previously approved for ages 14 and older.
On June 17, 2020 we issued a press release announcing FDA clearance of an expanded pediatric indication of the t:slim X2 insulin pump with Control-IQ technology. The accompanying press release is attached hereto as Exhibit 99.1 and is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
 





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:
/s/ David B. Berger
David B. Berger
Executive Vice President, Chief Legal & Compliance Officer
Date: June 17, 2020

 EX-99.01 2 exhibit991pressrelease.htm EX-99.01 Document
Exhibit 99.1
image01.jpg


FOR IMMEDIATE RELEASE
Tandem Diabetes Care Announces Expanded Pediatric Indication of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology
San Diego, CA – June 17, 2020 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of an expanded pediatric indication for the t:slim X2™ insulin pump with Control-IQ™ technology to children age six and older. The product was previously approved for ages 14 and older. Control-IQ technology is an advanced hybrid closed-loop feature designed to increase time in range (70-180 mg/dL).1
Control-IQ technology helps simplify diabetes management for younger patients by adjusting insulin delivery to help prevent highs and lows, automatically delivering correction boluses up to once per hour, and offering exercise and sleep-specific features. Integrated with Dexcom G6 continuous glucose monitoring (CGM), Control-IQ technology requires no fingersticks for calibration or diabetes treatment decisions.2
In a recent six-month study of children age 6 to 13 using the t:slim X2 pump with Control-IQ technology, sensor time in range (TIR) increased to 67 percent from 53 percent compared to those in the control group using sensor-augmented pump (SAP) alone (p<0.001). Overnight, children using Control-IQ technology in the same study stayed in range an average of 80 percent of the time, compared to 54 percent in the control group. This data from the International Diabetes Closed Loop Protocol-5 (DCLP5) study, funded by the National Institutes of Health (NIH), was presented earlier this year at the 13th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Madrid, Spain.3
“Nearly 40,000 t:slim X2 users have updated their pump with our revolutionary Control-IQ technology,” said John Sheridan, president and CEO of Tandem Diabetes Care. “The overwhelmingly positive benefits that people report experiencing can now be offered to a broader group of children with diabetes, which is particularly important as younger people often struggle with their glucose control.”
Benefits of Control-IQ Advanced Hybrid Closed-Loop Technology:
Predicts and helps prevent lows and highs – Control-IQ technology uses CGM readings to predict glucose values 30 minutes ahead. If glucose values are predicted to drop below 112.5 mg/dL, basal insulin delivery is reduced, and when predicted to be below 70 mg/dL, basal insulin delivery is stopped. If glucose values are predicted to be above 160 mg/dL in the next 30 minutes, basal insulin will be increased to help keep glucose in range (70-180 mg/dL).1
Automatic Correction Boluses – If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus with a target of 110 mg/dL and delivers 60 percent of that value. It will do this up to once an hour as needed.4
Accommodates for sleep and exercise – Control-IQ technology offers optional settings for sleep and exercise that change the treatment values to better match the different physiologic needs during these activities.
No fingersticks – With Dexcom G6 CGM integration, the Control-IQ feature works with no fingersticks required for mealtime dosing or calibration.2 Other benefits of the Dexcom G6 CGM include an extended 10-day wear, acetaminophen blocking,5 and the ability to share real-time CGM data with up to 10 followers.6
1
Exhibit 99.1
Standard Features of the t:slim X2 Insulin Pump:
Color touchscreen – The large color touchscreen on the t:slim X2 pump is easy to read, simple to learn, and intuitive to use for anyone familiar with a smartphone or tablet.
Small and discreet – The t:slim X2 pump is up to 38 percent smaller than other pumps,7 yet can hold up to 300-units of insulin.
Can be used with or without the Control-IQ feature or CGM – When advanced features are turned off, the t:slim X2 pump removes the CGM chart from the screen and puts the Bolus and Option buttons front and center for easy access.
For additional product and safety information, or to begin the order process, visit http://tandemdiabetes.com/controliq
Important Safety Information for the t:slim X2 insulin pump with Control-IQ technology
Caution: RX ONLY. The t:slim X2 pump and Control-IQ technology are intended for single patient use. The t:slim X2 pump and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The t:slim X2 pump is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of type 1 diabetes mellitus in persons six years of age and greater.
BOXED WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.
Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.
Insulin Pump Use and Diabetes
Diabetes is a chronic, life-threatening disease that affects more than 30 million people in the United States, or nearly 1 in 10 Americans. Tandem estimates that more than three million people in the United States require daily administration of insulin and are candidates for pump therapy. More than 500,000 Americans with type 1 diabetes use an insulin pump, or approximately 30 percent of the type 1 diabetes population. In addition, approximately 100,000 Americans with type 2 diabetes use an insulin pump, which is less than 10 percent of the type 2 diabetes population using intensive insulin therapy management.
2
Exhibit 99.1
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 pump is capable of remote feature updates using a personal computer, and is the only automated insulin dosing device approved for children as young as 6 years old. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark, and t:slim X2 and Control-IQ are trademarks of Tandem Diabetes Care, Inc. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. All other third-party marks are the property of their respective owners.
---------------
1. As measured by CGM
2. Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 CGM integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Dexcom G6 CGM sold separately. Dexcom transmitter can only be paired with one medical device (either a Dexcom receiver or t:slim X2 pump) and one consumer device (phone or tablet) at the same time.
3. Wadwa RP. Impact of Control-IQ on glycemic control for school age children with T1D. Industry Symposium. ATTD, Madrid, Spain; February 20, 2020.  https://www.youtube.com/watch?v=Tb-2NIify90&feature=youtu.be
4. If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60 percent of that value. It will do this up to once per hour as needed. An Automatic Correction Bolus will not occur within 60 minutes of a bolus that has been delivered or cancelled.
5. G6 readings can be used to make diabetes treatment decisions when taking up to a maximum acetaminophen dose of 1,000 mg every six hours. Taking a higher dose may affect the G6 readings.
6. Requires separate Dexcom Follow app.
7. 38% smaller than MiniMed 630G and 670G and at least 28% smaller than MiniMed 530G, Animas Vibe, and Omnipod System. Data on file, Tandem Diabetes Care.
# # #

Tandem Diabetes Care Contact Information:
Media: Steve Sabicer, 714-907-6264, ssabicer@thesabicergroup.com
Investors: Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com

3
 EX-101.SCH 3 tndm-20200616.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 tndm-20200616_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 tndm-20200616_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 tndm-20200616_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 tndm-20200616_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 image01.jpg GRAPHIC begin 644 image01.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page Cover Page
Jun. 16, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 16, 2020
Entity Registrant Name Tandem Diabetes Care, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36189
Entity Tax Identification Number 20-4327508
Entity Address, Address Line One 11075 Roselle Street
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 366-6900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TNDM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001438133
XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Cover Page Sheet http://www.tandemdiabetes.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports tndm-20200616.htm exhibit991pressrelease.htm tndm-20200616.xsd tndm-20200616_cal.xml tndm-20200616_def.xml tndm-20200616_lab.xml tndm-20200616_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tndm-20200616.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "tndm-20200616_cal.xml" ] }, "definitionLink": { "local": [ "tndm-20200616_def.xml" ] }, "inline": { "local": [ "tndm-20200616.htm" ] }, "labelLink": { "local": [ "tndm-20200616_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "tndm-20200616_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "tndm-20200616.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tndm", "nsuri": "http://www.tandemdiabetes.com/20200616", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tndm-20200616.htm", "contextRef": "if82e972a8e704a679129a62234d6f2ce_D20200616-20200616", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page Cover Page", "role": "http://www.tandemdiabetes.com/role/CoverPageCoverPage", "shortName": "Cover Page Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tndm-20200616.htm", "contextRef": "if82e972a8e704a679129a62234d6f2ce_D20200616-20200616", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 12 tndm-20200616_htm.xml IDEA: XBRL DOCUMENT 0001438133 2020-06-16 2020-06-16 false 0001438133 8-K 2020-06-16 Tandem Diabetes Care, Inc. DE 001-36189 20-4327508 11075 Roselle Street 92121 San Diego CA 858 366-6900 false false false false Common Stock, par value $0.001 per share TNDM NASDAQ false ZIP 13 0001438133-20-000095-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001438133-20-000095-xbrl.zip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end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $6;T5 ?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 19O14"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !%F]%0"(&ULS9+!:L,P#(9?9?B>R$DA92;U96.G%@8K;.QF;+4UBV-C:R1]^R5> MFS*V!]C1TN]/GT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2.27ZJ7GP MT2F:GO$(0>D/=42H.6_ (2FC2,$,+,)"9+(U6NB(BGR\X(U>\.$S=AEF-&"' M#GM*4)45,#E/#.>Q:^$&F&&$T:7O IJ%F*M_8G,'V"4Y)KNDAF$HAU7.33M4 M\+;;ON1U"]LG4KW&Z5>R@LX!-^PZ^77U\+A_8K+F-2]X4U3K?74OZD;P]?OL M^L/O)NR\L0?[CXVO@K*%7W&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " !%F]%0%8NU-IT" "8"P & 'AL+W=O@,IK83 MKF]?&SB*O.L_8)N9'9MAQ.XZJ=YTR;F)WFO1Z'U<&M-NDT2?2UXS_21;WM@G M5ZEJ9NQ4W1+=*LXN/:D6"4W395*SJHF+7;]V5,5.WHVH&GY4D;[7-5-_#US( M;A^3^&/AI;J5QBTDQ:YE-_Z3FU_M4=E9,E6Y5#5O="6;2/'K/OY$M@>:.T*/ M>*UXIV?CR!WE).6;FWR[[./4[8@+?C:N!+.W!W_F0KA*=A]_QJ+QI.F(\_%' M]2_]X>UA3DSS9RE^5Q=3[N-U'%WXE=V%>9'=5SX>:!%'X^F_\P<7%NYV8C7. M4NC^&IWOVLAZK&*W4K/WX5XU_;T;GN3Y2,,)="30_X3A+(-0O_//S+!BIV07 MJ>'EM\QY3+;4OINS6^Q?1?_,;E[;U4>1[I*'*S,B#@."SA!D0B2V]B1 40': MT[,9G>+T#*5G/3V?T3-O?Q"1XP(Y*I #^L(3@(@E+K! !1: OO($(&*-"RQ1 M@26@;SP!B" IKK!"%5:03SP)!!+P>8U*K"'?-QJ!!)S>H!(;R/>M1B !KTF* MQRF%%7R[,4S YIX)A%@$5//L4YCI;^BH( M9A50"?RU8:ZSM:^"9#_@"\6S3Y&_N_\E(YB@"IY]"G.=^U\RAO';G&364[F> M]0=3MZK1T4D:VY[U3=152L-MO?3)IKRT;?(T$?QJW'!EQVKH%8>)D>W8!R=3 M,U[\ U!+ P04 " !%F]%09]WL-%<" #^!0 % 'AL+W-H87)E9%-T M&ULA53;CMHP$'W>?L4(]:&5@%RX+%0L$@*V8B\LW2!5:M4'DPR) MU=A.;8>%O^\$VJZ$2?)4U5*>]/HA@W8BUR:FT9F M;?')\TR_W/<&X;(Q'AH]'=CQ5 M.]2P8BG"ZW'DV?'(JP GT%TIVQ#TFQ#ZH7\>/%W[/MD8JUEL?YS'9RHN!4H+ MZT/A, ]:][7X%6JN$IC+!&;,UHIZ=W5U2=9<6FX/\(PIKX01WY()AV3-9((" M9IQMT**!*=/8A(6,VS5\%%*Z4)I9KF03(DO*0&DX]D8?Z)LX26;S&K);GB,L M2[%!?8[P_:#5Z0>#8HODG\DK MK790MBI4REN7PC1<7.S0,@S!P6(\,M#X7KPQZCJ$/*J84RA4>R27.6GT-6&ELQ M,2-9=]I$I*G7\+3=NA(=\,*8DL#_N[/FEB9";2$(/VP^0H1Q204=W)="")K3 MR*KX9Q,*IF''\A+AO=^F<8>"Z$U&"^C0:Y94]44'L5%.=>OE[-$QY8\"F._C MC$EZW"XM_W(2S29?:D9G+E"G5=;/6KW8K&I-P:13TX0\2HX^W>8LK>&:4ES3 M:"S(PCW:%ID>U)/"GE1F MT)C3$V5%UAB](WN]*Z32=.7D&?PF1 MQ3Y/UBML'9^2])[N$^;!%RF-J\%M91*Z0D4FH0ERG&B[,**Q+ 01C?)&+7AK M-)\UK#,6P]-6(.5+.,*OS17WV)"8\[$.QT""BM7TJU[,>%S1"?Q'MLA]H+V_ MB998<3'X8?"KT;/_;3 (SPX:,<[^V&SU/3NW5D[OI6BU@KB6WQ9,;BQ89'RM M0SKCQ*OG"S>E\@ X2B[@4%1'Y+OC]@PCKK=I;&[5G/Z'FO_V/K>@P7%Y%.VO M_K^\RW^BF"W=>&%S.F7\/#*JS[9^]33(R_] M W[%[^?6T/!!XG-8\1S,Z6Y_"B]-\K!EG3>*G.[V9ZC%H-[.!?>_1/$#4$L# M!!0 ( $6;T5#B&PO=V]R:V)O;VLN>&ULC5'! M;L(P#/V5*!^P%K0A#5$NH&U(TX;&Q#UM76J1Q)438./KYP9UL-M.L9_M9[^7 MV8EX7Q+MU9>S/A2ZC;&;9EFH6G FW%$'7BH-L3-14MYEH6,P=6@!HK/9.,\G MF3/H]7PV<*TYNTTH0A61O( ]L$4XA6N]3Y61AB-\FK+0N5;F$.D);01>F@C/ M3(<._:[0(ZT:Y! W_>[4Z="CPS/4*0LMG5Z(\4P^&KNIF*Q-4WTA#@46]"B(KN1D7P8WHN)4_Z/C=0T6,&2 MJH,#'R\^,MA^NP\M=D$K;QP4>D%'8+4V.U#7L%<@"U?U14T4GZXG*IZB%'A5 MC]*YPXTU-.BA?A/:(+A(K]:L^B?QC.\?1H]B\<':A6#O_I5,XN\YAN^:_P!0 M2P,$% @ 19O14/_ )@B] A0( !H !X;"]? *A0V$LZ&8O:3RKC>LG^Z&JP MLFAEC1"'X17FP?+)K=$U'AZS@>S'G10R/'1Y?,5'W M])=9SUZ",*V'O\E$_37 ZM=E7U!+ P04 " !%F]%0"X_8 R$! !7! M$P %M#;VYT96YT7U1Y<&5S72YX;6RU5$U/PS ,_2M3KVC-X, !;;L 5Y@$ M?R D;ALU7[*]T?U[W&Y#8BIB:-LEB?/L]UX2*_/W;0::=,%'6A0-BVD1[1#K=$Y8(?LBAQF6ZD81B\MP)"\G>HA"4"G6"PG%A'TO=ZP80 MG85_64M5Y0S89-9!2DK*"-I2 \#!E]1H!/O&Z&*]][O2R"\Z"+'JO/J14%[/ M!V\]C!L8D$LJL[0%C$D-P&Z\/4OPT TF(4PS"HKL1HXGEE:"DNH3+WE$Z%O' M@CU)7*BO]["?"=MA/7;AWR"I83KOUO]H=)G+H%W\S&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( $6;T5 5B[4VG0( )@+ M 8 " ?@( !X;"]W;W)K&PO&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !% MF]%0"X_8 R$! !7! $P @ &U$@ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "@ * ( " '% ! end XML 16 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}